TRT progress sabotage claims: what the evidence actually shows

What did @drjonesdc actually say?

The core claim here is that repeated injections into the same spot cause lipohypertrophy, and that scar tissue "literally blocks absorption" of GLP-1 medications, potentially costing patients "15% of your GLP." The fix offered is a quadrant rotation system, keeping spots at least one inch apart and rotating weekly.

To be clear, this video is tagged under TRT but the content is entirely about GLP-1 injections, likely semaglutide or tirzepatide. That category mismatch matters because the audiences, injection techniques, and clinical stakes are different. We'll fact-check what was actually said.

Does the science back this up?

Yes, largely. Lipohypertrophy at insulin and GLP-1 injection sites is a well-documented problem, and its effect on drug absorption is real and clinically meaningful. The 15% figure, though, needs scrutiny.

The strongest evidence base here comes from insulin research. Famously, Blanco et al. (2013, Diabetes Care) found that 49% of people with type 1 diabetes injected into lipohypertrophic tissue without knowing it, and those patients had significantly worse glycemic control. Chowdhury et al. (2017, Diabetologia) demonstrated that insulin absorption from lipohypertrophic sites was measurably delayed and inconsistent compared to healthy tissue. The mechanism is real: fibrotic subcutaneous tissue disrupts the vascularity that normally allows drug diffusion into systemic circulation.

For GLP-1 receptor agonists specifically, the direct research is thinner. These medications are not insulin, and their pharmacokinetic profiles differ. Semaglutide, for instance, has a half-life of approximately seven days. Whether lipohypertrophy affects absorption of long-acting GLP-1 medications to the same degree as short-acting insulin is genuinely unknown from published data. The creator extrapolates from insulin science to GLP-1s, which is a reasonable clinical inference but not a proven fact.

What did they get wrong (or right)?

The creator got the mechanism right and the practical advice right. Lipohypertrophy is real, it does impair absorption, and rotation does prevent it. Credit where it is due.

The "15%" figure is the problem. It is stated with confidence, without a source, and without any qualifier. A number like that implies precision from clinical measurement. No published study we are aware of has quantified GLP-1 absorption loss specifically at 15% due to lipohypertrophy. The figure may be a rough extrapolation from insulin studies or clinical observation, but presenting it as a specific, reliable number to a 94,000-person audience is misleading. It will be screenshot and shared as fact.

The framing that patients "think they need a higher dose" but the real problem is injection technique is also worth examining. In some cases, yes. In other cases, GLP-1 dose escalation is clinically appropriate for efficacy reasons unrelated to technique. Presenting injection site rotation as a plateau cure-all oversimplifies what is often a multifactorial situation involving diet adherence, metabolic adaptation, and appropriate titration under medical supervision.

What should you actually know?

Injection site rotation is standard of care for subcutaneous medications, and it is genuinely underemphasized in patient education. Studies on insulin populations show that many patients develop lipohypertrophy without realizing it, and the clinical consequences are real.

If you are on a GLP-1 medication and feel like it has stopped working, injection technique is worth reviewing, but it is one variable among several. Dose timing, storage temperature, injection depth, and concomitant dietary changes all matter. A subcutaneous injection into fatty tissue should reach 4 to 6 mm depth; injecting too superficially or too deep affects delivery regardless of site rotation.

The quadrant rotation advice is practical and consistent with guidance from organizations like the American Diabetes Association. Rotating sites within an area, not just between areas, and maintaining at least 1 to 2 cm between injection points is supported by clinical consensus even where direct GLP-1 trial data is sparse.

One thing this video does not address: some patients on weekly GLP-1 injections rotate correctly and still plateau. That plateau often has nothing to do with injection technique and everything to do with physiology. Do not self-adjust your dose based on a TikTok video. That is a conversation for your prescribing clinician.